Compare Stocks: PLUR, ANVS, BKHA, and TVGN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANVS Annovis Bio	$1.33 +4.6%	$1.60	$1.04 ▼ $5.50	$53.78M	1.24	1.31 million shs	853,917 shs
BKHA Black Hawk Acquisition	$12.47 +3.1%	$11.94	$11.00 ▼ $13.10	$50.26M	0.04	619 shs	465 shs
PLUR Pluri	$1.05 -0.9%	$1.52	$0.98 ▼ $4.87	$13.58M	0.68	27,955 shs	14,469 shs
TVGN Tevogen Bio	$7.85 +0.5%	$6.63	$3.64 ▼ $43.66	$50.85M	0.17	7,951 shs	2,919 shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANVS Annovis Bio	+4.16%	+21.06%	-26.83%	-21.65%	-39.64%
BKHA Black Hawk Acquisition	+3.02%	+4.06%	+5.78%	+3.96%	+12.06%
PLUR Pluri	-0.94%	-2.78%	-36.75%	-52.60%	-76.56%
TVGN Tevogen Bio	+1.15%	+1.82%	+12.63%	+12.14%	-79.71%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANVS Annovis Bio	$1.33 +4.6%	$1.60	$1.04 ▼ $5.50	$53.78M	1.24	1.31 million shs	853,917 shs
BKHA Black Hawk Acquisition	$12.47 +3.1%	$11.94	$11.00 ▼ $13.10	$50.26M	0.04	619 shs	465 shs
PLUR Pluri	$1.05 -0.9%	$1.52	$0.98 ▼ $4.87	$13.58M	0.68	27,955 shs	14,469 shs
TVGN Tevogen Bio	$7.85 +0.5%	$6.63	$3.64 ▼ $43.66	$50.85M	0.17	7,951 shs	2,919 shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANVS Annovis Bio	+4.16%	+21.06%	-26.83%	-21.65%	-39.64%
BKHA Black Hawk Acquisition	+3.02%	+4.06%	+5.78%	+3.96%	+12.06%
PLUR Pluri	-0.94%	-2.78%	-36.75%	-52.60%	-76.56%
TVGN Tevogen Bio	+1.15%	+1.82%	+12.63%	+12.14%	-79.71%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANVS Annovis Bio	2.25	Hold	$12.00	803.61% Upside
BKHA Black Hawk Acquisition	1.00	Sell	N/A	N/A
PLUR Pluri	1.00	Sell	N/A	N/A
TVGN Tevogen Bio	1.50	Reduce	$100.00	1,173.89% Upside

Current Analyst Ratings Breakdown

Latest PLUR, ANVS, BKHA, and TVGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/27/2026	ANVS Annovis Bio	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$8.00 ➝ $7.00
8/26/2026	PLUR Pluri	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/18/2026	ANVS Annovis Bio	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/11/2026	PLUR Pluri	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/23/2026	PLUR Pluri	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/17/2026	BKHA Black Hawk Acquisition	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D)
7/17/2026	TVGN Tevogen Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/9/2026	ANVS Annovis Bio	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
7/7/2026	ANVS Annovis Bio	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$8.00
7/7/2026	PLUR Pluri	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/7/2026	ANVS Annovis Bio	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 9/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANVS Annovis Bio	N/A	N/A	N/A	N/A	$0.64 per share	N/A
BKHA Black Hawk Acquisition	N/A	N/A	N/A	N/A	N/A	N/A
PLUR Pluri	$1.02M	12.71	N/A	N/A	($1.62) per share	-0.65
TVGN Tevogen Bio	N/A	N/A	N/A	N/A	($211.84) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANVS Annovis Bio	-$28.85M	-$1.79	N/A	N/A	N/A	N/A	-685.98%	-258.77%	11/11/2026 (Estimated)
BKHA Black Hawk Acquisition	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PLUR Pluri	-$23.82M	-$2.45	N/A	N/A	N/A	-2,344.59%	N/A	-82.71%	11/5/2026 (Estimated)
TVGN Tevogen Bio	-$26.27M	-$4.63	N/A	N/A	N/A	N/A	N/A	-468.32%	11/13/2026 (Estimated)

Latest PLUR, ANVS, BKHA, and TVGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/10/2026	Q4 2026	PLUR Pluri	-$0.66	-$0.54	+$0.12	-$0.54	$0.66 million	$0.34 million
8/14/2026	Q2 2026	ANVS Annovis Bio	-$0.4533	-$0.40	+$0.0533	-$0.40	N/A	N/A
8/14/2026	Q2 2026	TVGN Tevogen Bio	-$2.53	-$1.52	+$1.01	-$1.52	N/A	N/A
7/15/2026	Q2 2026	BKHA Black Hawk Acquisition	N/A	$0.02	N/A	$0.02	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANVS Annovis Bio	N/A	N/A	N/A	N/A	N/A
BKHA Black Hawk Acquisition	N/A	N/A	N/A	N/A	N/A
PLUR Pluri	N/A	N/A	N/A	N/A	N/A
TVGN Tevogen Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANVS Annovis Bio	N/A	3.47	3.47
BKHA Black Hawk Acquisition	N/A	N/A	N/A
PLUR Pluri	N/A	0.27	0.27
TVGN Tevogen Bio	N/A	0.33	0.33

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANVS Annovis Bio	15.83%
BKHA Black Hawk Acquisition	N/A
PLUR Pluri	16.59%
TVGN Tevogen Bio	N/A

Insider Ownership

Company	Insider Ownership
ANVS Annovis Bio	15.92%
BKHA Black Hawk Acquisition	N/A
PLUR Pluri	43.16%
TVGN Tevogen Bio	65.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANVS Annovis Bio	7	42.68 million	35.89 million	Optionable
BKHA Black Hawk Acquisition	N/A	4.15 million	N/A	N/A
PLUR Pluri	113	12.35 million	7.02 million	No Data
TVGN Tevogen Bio	3	6.51 million	2.24 million	N/A

PLUR, ANVS, BKHA, and TVGN Headlines

Recent News About These Companies

Tevogen Bio (NASDAQ:TVGN) Stock Price Up 5.1% - Time to Buy?

September 23 at 2:21 AM | americanbankingnews.com

Tevogen Bio Holdings Rebrands as Tevogen Inc.

July 30, 2026 | tipranks.com

Tevogen Bio Holdings Corporate Event Calendar | NASDAQ:TVGN

July 24, 2026 | benzinga.com

Tevogen Bio Announces 2026 Annual Meeting of Stockholders

July 13, 2026 | globenewswire.com

Tevogen Bio Inc: Tevogen Announces Formation of a Healthcare Services Initiative

June 10, 2026 | finanznachrichten.de

Tevogen Bio Holdings Inc. Announces William Keane as Interim Head of New Healthcare Services Initiative, Exploring MSO and CRO Acquisitions

June 9, 2026 | quiverquant.comQ

Tevogen Announces Formation of a Healthcare Services Initiative

June 9, 2026 | globenewswire.com

Tevogen Bio Inc: Tevogen Advances Strategic Acquisition Initiatives with Potential to Support Approximately $100 Million in Combined Annual Revenue

May 28, 2026 | finanznachrichten.de

Tevogen Advances Strategic Acquisition Initiatives with Potential to Support Approximately $100 ...

May 28, 2026 | enidnews.comE

Tevogen Advances Strategic Acquisition Initiatives with Potential to Support Approximately $100 Million in Combined Annual Revenue

May 28, 2026 | globenewswire.com

Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Management Services ...

May 21, 2026 | caledonianrecord.comC

Tevogen Bio Holdings Inc. Signs Non-Binding Letter of Intent to Explore Strategic Healthcare Transaction

May 21, 2026 | quiverquant.comQ

Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Management Services Organization

May 21, 2026 | globenewswire.com

Tevogen Bio Holdings Inc. Reports Significant Operational Improvements and Strategic Growth Initiatives

May 18, 2026 | quiverquant.comQ

Letter to Shareholders from CEO Dr. Ryan Saadi

May 18, 2026 | globenewswire.com

Tevogen Announces $3 Million Private Investment at $8 Per Share, a 14% Premium from Latest ...

May 12, 2026 | caledonianrecord.comC

Tevogen Bio Holdings Inc. Secures $3 Million PIPE Financing from The Patel Family, LLP

May 12, 2026 | quiverquant.comQ

Tevogen Announces $3 Million Private Investment at $8 Per Share, a 14% Premium from Latest Market Close

May 12, 2026 | globenewswire.com

Tevogen (TVGN) Soars 11% as Firm Gears Up for AI Training Commercialization

May 5, 2026 | finance.yahoo.com

Tevogen.AI Nears Completion of PredicTcell™ Training; Initiates Commercial Readiness and Debuts Internal Application Portal

April 27, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLUR, ANVS, BKHA, and TVGN Company Descriptions

Annovis Bio NYSE:ANVS

$1.33 +0.06 (+4.57%)

Closing price 09/24/2026 03:59 PM Eastern

Extended Trading

$1.35 +0.03 (+1.96%)

As of 07:27 AM Eastern

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.

Black Hawk Acquisition NASDAQ:BKHA

$12.47 +0.37 (+3.07%)

As of 09/24/2026 03:50 PM Eastern

Black Hawk Acquisition Corporation focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2023 and is based in Danville, California.

Pluri NASDAQ:PLUR

$1.05 -0.01 (-0.94%)

Closing price 09/24/2026 04:00 PM Eastern

Extended Trading

$1.02 -0.03 (-2.38%)

As of 09/24/2026 04:10 PM Eastern

Pluri Inc., a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production. The company's development pipeline includes PLX-PAD, is composed of maternal mesenchymal stromal cells originating from the placenta that is currently under phase III study for orthopedic, phase II study for COVID-19, and phase I/II clinical study for Steroid-Refractory cGVHD indications; and PLX-R18, is composed of fetal MSC like cells originating from the placenta that is currently under phase I study for HCT and pilot study for ARS indications. It is also involved in the development of modified PLX cells. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.

Tevogen Bio NASDAQ:TVGN

$7.85 +0.04 (+0.51%)

Closing price 09/24/2026 04:00 PM Eastern

Extended Trading

$7.61 -0.24 (-3.06%)

As of 07:32 AM Eastern

Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PLUR, ANVS, BKHA, and TVGN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PLUR, ANVS, BKHA, and TVGN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PLUR, ANVS, BKHA, and TVGN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLUR, ANVS, BKHA, and TVGN Company Descriptions

Annovis Bio NYSE:ANVS

Black Hawk Acquisition NASDAQ:BKHA

Pluri NASDAQ:PLUR

Tevogen Bio NASDAQ:TVGN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PLUR, ANVS, BKHA, and TVGN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PLUR, ANVS, BKHA, and TVGN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PLUR, ANVS, BKHA, and TVGN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLUR, ANVS, BKHA, and TVGN Company Descriptions

Annovis Bio NYSE:ANVS

Black Hawk Acquisition NASDAQ:BKHA

Pluri NASDAQ:PLUR

Tevogen Bio NASDAQ:TVGN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools